{"commentary":{"count":12,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":6,"youtube":4,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02272478\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"AML18","nct_id":"NCT02272478","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=aml18-nct02272478. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"AML18","arms":[{"description":"Patients not known adverse karyotype\n\nRandomise between\n\nDaunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy\n\nVersus\n\nCPX-351 100 units/m2 on days 1, 3 and 5","label":"Arm A","type":"ACTIVE_COMPARATOR"},{"description":"Patients with known adverse karyotype\n\n5 cycles of Vosaroxin and Decitabine therapy","label":"Arm B","type":"ACTIVE_COMPARATOR"},{"description":"Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1\n\nRandomise between\n\nDaunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)\n\nVersus\n\nDaunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive\n\nVersus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive\n\nPatients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)\n\nAnd Randomisation to receive AC220 or not","label":"Arm C","type":"ACTIVE_COMPARATOR"},{"description":"Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1\n\nRandomisation to receive AC220 or not","label":"Arm D","type":"ACTIVE_COMPARATOR"},{"description":"Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1\n\nRandomisation between\n\nCPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)","label":"Arm E","type":"ACTIVE_COMPARATOR"},{"description":"Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1\n\nRandomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)\n\nversus\n\nIntermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)","label":"Arm F","type":"ACTIVE_COMPARATOR"}],"collaborators":["Cancer Research UK"],"completion_date":{"date":"2022-02","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukaemia","Myelodysplastic Syndrome"],"enrollment":{"count":1600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Arm A Mylotarg plus DA Versus CPX-351","type":"DRUG"},{"name":"Arm B Vosaroxin and Decitabine","type":"DRUG"},{"name":"Arm D Small molecule or Not","type":"DRUG"},{"name":"Arm C DA V FLAG-Ida V DAC","type":"DRUG"},{"name":"Arm E CPX-351 (200 V 300)","type":"DRUG"},{"name":"Arm F DA V IDAC","type":"DRUG"}],"last_update":"2020-01-23","lead_sponsor":"Cardiff University","official_title":"A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2021-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"1 year"},{"measure":"Complete remission (CR + CRi) achievement and reasons for failure (for induction questions)","timeFrame":"1 month"},{"measure":"Duration of remission, relapse rates and deaths in first CR","timeFrame":"1 month"},{"measure":"Toxicity, both haematological and non-haematological","timeFrame":"1 month"},{"measure":"Supportive care requirements (and other aspects of health economics)","timeFrame":"6 months"}],"references":[{"citation":"Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew G, Dillon R, Gilkes A, Marquez Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne J, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills R, Freeman SD, Russell NH. CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial. Blood. 2026 Mar 5;147(10):1048-1057. doi: 10.1182/blood.2025031006.","pmid":"41237344","type":"DERIVED"}],"start_date":{"date":"2014-10-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations","url":"https://clinicaltrials.gov/study/NCT02272478"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/aml18-nct02272478"}